Potential usefulness of quinine to circumvent the anthracycline resistance in clinical practice

B. Chauffert; H. Pelletier; C. Corda; E. Solary; L. Bedenne; D. Caillot; F. Martin

doi:10.1038/bjc.1990.305

Potential usefulness of quinine to circumvent the anthracycline resistance in clinical practice

B. Chauffert, H. Pelletier, C. Corda, E. Solary, L. Bedenne, D. Caillot, F. Martin

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

32 Citations (Scopus)

Résumé

Quinine, the widely used antimalaria agent, was found to increase the cytotoxicity of epidoxo- rubicin (epiDXR) in resistant DHD/K12 rat colon cancer cells in vitro. Quinine appeared as slightly less effective than quinidine or verapamil for anthracycline potentiation but its weaker cardiotoxicity could counterbalance this disadvantage in vivo. Serum from six patients treated by conventional doses of quinine (25-30 mg kg^-1 day^-1) was demonstrated to enhance the accumulation of epiDXR in DHD/K12 cells as judged by fluorescence microscopy and HPLC assay (1.6 to 6-fold compared with control serum). In this patients quinine concentrations in serum ranged from 4.4 to 10.1 µg ml^-1. Our results suggest that quinine could be safely used as anthracycline resistance modifier in clinical practice.

langue originale	Anglais
Pages (de - à)	395-397
Nombre de pages	3
journal	British Journal of Cancer
Volume	62
Numéro de publication	3
Les DOIs	https://doi.org/10.1038/bjc.1990.305
état	Publié - 1 janv. 1990
Modification externe	Oui

Accès au document

10.1038/bjc.1990.305

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{486978c86c894daf8cff728086ddddf9,

title = "Potential usefulness of quinine to circumvent the anthracycline resistance in clinical practice",

abstract = "Quinine, the widely used antimalaria agent, was found to increase the cytotoxicity of epidoxo- rubicin (epiDXR) in resistant DHD/K12 rat colon cancer cells in vitro. Quinine appeared as slightly less effective than quinidine or verapamil for anthracycline potentiation but its weaker cardiotoxicity could counterbalance this disadvantage in vivo. Serum from six patients treated by conventional doses of quinine (25-30 mg kg-1 day-1) was demonstrated to enhance the accumulation of epiDXR in DHD/K12 cells as judged by fluorescence microscopy and HPLC assay (1.6 to 6-fold compared with control serum). In this patients quinine concentrations in serum ranged from 4.4 to 10.1 µg ml-1. Our results suggest that quinine could be safely used as anthracycline resistance modifier in clinical practice.",

author = "B. Chauffert and H. Pelletier and C. Corda and E. Solary and L. Bedenne and D. Caillot and F. Martin",

year = "1990",

month = jan,

day = "1",

doi = "10.1038/bjc.1990.305",

language = "English",

volume = "62",

pages = "395--397",

journal = "British Journal of Cancer",

issn = "0007-0920",

number = "3",

}

TY - JOUR

T1 - Potential usefulness of quinine to circumvent the anthracycline resistance in clinical practice

AU - Chauffert, B.

AU - Pelletier, H.

AU - Corda, C.

AU - Solary, E.

AU - Bedenne, L.

AU - Caillot, D.

AU - Martin, F.

PY - 1990/1/1

Y1 - 1990/1/1

N2 - Quinine, the widely used antimalaria agent, was found to increase the cytotoxicity of epidoxo- rubicin (epiDXR) in resistant DHD/K12 rat colon cancer cells in vitro. Quinine appeared as slightly less effective than quinidine or verapamil for anthracycline potentiation but its weaker cardiotoxicity could counterbalance this disadvantage in vivo. Serum from six patients treated by conventional doses of quinine (25-30 mg kg-1 day-1) was demonstrated to enhance the accumulation of epiDXR in DHD/K12 cells as judged by fluorescence microscopy and HPLC assay (1.6 to 6-fold compared with control serum). In this patients quinine concentrations in serum ranged from 4.4 to 10.1 µg ml-1. Our results suggest that quinine could be safely used as anthracycline resistance modifier in clinical practice.

AB - Quinine, the widely used antimalaria agent, was found to increase the cytotoxicity of epidoxo- rubicin (epiDXR) in resistant DHD/K12 rat colon cancer cells in vitro. Quinine appeared as slightly less effective than quinidine or verapamil for anthracycline potentiation but its weaker cardiotoxicity could counterbalance this disadvantage in vivo. Serum from six patients treated by conventional doses of quinine (25-30 mg kg-1 day-1) was demonstrated to enhance the accumulation of epiDXR in DHD/K12 cells as judged by fluorescence microscopy and HPLC assay (1.6 to 6-fold compared with control serum). In this patients quinine concentrations in serum ranged from 4.4 to 10.1 µg ml-1. Our results suggest that quinine could be safely used as anthracycline resistance modifier in clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=0025128368&partnerID=8YFLogxK

U2 - 10.1038/bjc.1990.305

DO - 10.1038/bjc.1990.305

M3 - Article

C2 - 2206948

AN - SCOPUS:0025128368

SN - 0007-0920

VL - 62

SP - 395

EP - 397

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 3

ER -